TP53 and prostate cancer: The Mdm2 gene, encoding an E3 ubiquitin ligase enzyme that is a key negative regulator of p53, is amplified in around 7% of all tumors as an alternative means of inactivating p53, although this rarely occurs in prostate cancer [15].